Toulouse, France, and Salem, MA, US, October 16th, 2023 –
Genoskin, a biotechnology company that leverages live ex vivo human skin to test therapeutic and non-therapeutic products, today announces the launch of its new service, VaxSkin®. This unique service is poised to transform vaccine development by identifying key immune responses and delivering essential data in the early stages, ahead of clinical trials.
VaxSkin® is powered by the innovative HypoSkin® technology, which combines bio-stabilized, immunocompetent ex vivo human skin with multiomic assays and computational molecular pathway analysis. This holistic approach offers a wealth of insights into human immune responses to vaccine injection, enabling researchers to advance their studies with precision and confidence.
Key Features of VaxSkin® Include:
-
Human-Centric Data: VaxSkin® provides invaluable human-centric data prior to initiating clinical trials, ensuring more accurate and reliable data.
-
Comprehensive Testing: Customers can test various vaccine formulations and doses using a single donor, optimizing the research process.
-
Diverse Human Responses: VaxSkin® mimics responses in diverse human populations, ensuring a comprehensive understanding of the vaccine’s impact.
-
Advanced Technologies: Incorporates multiplex cytokine release assays, bulk RNA sequencing, single-cell RNA sequencing, and MANTIS® multiplex spatial imaging.
About Genoskin
Genoskin stands at the forefront of transformative non-clinical platforms, specializing in leveraging human skin to test therapeutic and non-therapeutic products. Founded in 2011 as a spin-off of the French National Center for Scientific Research (CNRS) and The Paul Sabatier University in Toulouse, Genoskin has been steadfast in its commitment to providing a reliable alternative to animal-based experiments. Utilizing real human tissues ethically sourced from plastic surgeries and cutting-edge technologies, Genoskin ensures the viability, immunocompetency, and functionality of human skin samples, promoting safer and more effective drug development.
VaxSkin® is a testament to Genoskin’s unwavering dedication to innovation and excellence in the realm of non-clinical testing and vaccine development. For more information about VaxSkin® and Genoskin’s transformative services, please visit our website.
Media Contact:
Lorna Santos, VP of Marketing and Product Management
marketing@genoskin.com